Replies to post #227660 on Biotech Values

[miljenko]

Sales will continue to increase, 2020 and after. No question about. What would be peak sale? Not easy to predict, to many factors.

However, as I see there should not be increase. My view is wrong, I can live with it, but I will not change bit of it. Omega-3 (EPA, DHA, PDA, ...) pure or in mix, whatever) should be OTC drug. When compound/molecule is endogenous, UFA or Q-3, supplementation is a way to increase level to *therapeutic* level.

Lebel does not explicitly describe subject WITH CV event, but from conditions it is not far away. So, it is not for *ANYONE WHO IS FAT*!

[DewDiligence]

After all the commotion on Friday, AMRN was -5% today.

Although peak-sales estimates for Vascepa are all over the map and the drug’s patent is in litigation, one thing is clear: the fully-diluted enterprise value is about $8.8B.